Wells Fargo & Company MN lessened its stake in NxStage Medical, Inc. (NASDAQ:NXTM) by 5.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 660,331 shares of the medical device company’s stock after selling 37,070 shares during the period. Wells Fargo & Company MN owned about 1.00% of NxStage Medical worth $16,000,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Gamco Investors INC. ET AL lifted its stake in shares of NxStage Medical by 10.2% in the 4th quarter. Gamco Investors INC. ET AL now owns 24,403 shares of the medical device company’s stock valued at $591,000 after acquiring an additional 2,250 shares during the last quarter. Quantbot Technologies LP increased its holdings in NxStage Medical by 22.8% during the 3rd quarter. Quantbot Technologies LP now owns 13,190 shares of the medical device company’s stock valued at $364,000 after purchasing an additional 2,452 shares during the period. Aperio Group LLC increased its holdings in NxStage Medical by 36.8% during the 3rd quarter. Aperio Group LLC now owns 11,123 shares of the medical device company’s stock valued at $307,000 after purchasing an additional 2,990 shares during the period. American International Group Inc. increased its holdings in NxStage Medical by 8.1% during the 3rd quarter. American International Group Inc. now owns 43,543 shares of the medical device company’s stock valued at $1,202,000 after purchasing an additional 3,256 shares during the period. Finally, Public Employees Retirement Association of Colorado purchased a new position in NxStage Medical during the 4th quarter valued at about $128,000. 84.26% of the stock is owned by institutional investors.
In related news, SVP Winifred L. Swan sold 3,500 shares of the business’s stock in a transaction dated Wednesday, December 20th. The stock was sold at an average price of $25.35, for a total transaction of $88,725.00. Following the transaction, the senior vice president now owns 14,270 shares in the company, valued at approximately $361,744.50. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders have sold 10,500 shares of company stock worth $261,485. 4.70% of the stock is owned by company insiders.
A number of research analysts recently issued reports on NXTM shares. BidaskClub downgraded NxStage Medical from a “sell” rating to a “strong sell” rating in a report on Thursday, February 15th. ValuEngine downgraded NxStage Medical from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. Finally, Zacks Investment Research upgraded NxStage Medical from a “sell” rating to a “hold” rating in a report on Friday, January 26th. Three research analysts have rated the stock with a sell rating and eight have assigned a hold rating to the company’s stock. NxStage Medical has an average rating of “Hold” and a consensus price target of $30.25.
TRADEMARK VIOLATION NOTICE: This piece of content was posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/03/14/wells-fargo-company-mn-sells-37070-shares-of-nxstage-medical-inc-nxtm.html.
NxStage Medical Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.